RxDoctor Payments Data

Christopher Tully

Hematology · Mountain Lakes, NJNPI 1053585232

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 1,097 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,549 and has fallen 56.0% since, to $2,001 in 2025.

$17,494in general payments, 2019–2025

Across 1,097 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Seagen Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Merck$946
  • Johnson & Johnson$930
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1,1507%
  • Food & beverage$16,26993%
  • Education$750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)106$1,815
Seagen Inc.32$1,587
E.r. Squibb & Sons, L.L.C.100$1,403
Novartis80$1,038
Merck68$946
Johnson & Johnson(2 entities)68$930
Incyte Corporation60$873
Amgen(2 entities)69$813
Daiichi Sankyo Inc.34$567
GSK31$500
Genentech USA, Inc.34$479
Bayer29$413
Eisai Inc.18$384
Astellas Pharma US Inc24$344
Gilead(2 entities)20$329
Sanofi21$319
AbbVie21$304
Ipsen Biopharmaceuticals, Inc12$299
Bristol Myers Squibb22$295
Regeneron Healthcare Solutions, Inc.17$262
Pfizer16$233
Lilly USA, LLC19$188
Puma Biotechnology, Inc.14$171
Mirati Therapeutics, Inc.10$161
Foundation Medicine, Inc.5$145
Verastem, Inc.9$142
Takeda Pharmaceuticals U.S.A., Inc.9$140
Kyowa Kirin, Inc.9$136
Celltrion USA Inc.2$129
Pharmacyclics LLC, An Abbvie Company9$126
Taiho Oncology, Inc.6$107
Blueprint Medicines Corporation6$105
Beigene USA, Inc.7$104
Myriad Genetic Laboratories, Inc.6$96
Exelixis Inc.6$94
Genmab U.S., Inc.6$93
Karyopharm Therapeutics Inc.6$93
Boehringer Ingelheim6$84
Pharmacosmos Therapeutics Inc.5$81
CTI Biopharma Corp.5$72
AMAG Pharmaceuticals, Inc.5$64
Pharmaessentia USA Corporation4$63
Adaptive Biotechnologies Corporation4$62
EMD Serono, Inc.4$59
Rigel Pharmaceuticals, Inc.4$56
AVEO Pharmaceuticals, Inc.3$55
Servier Pharmaceuticals LLC3$54
Array Biopharma Inc3$49
Epizyme, Inc.3$43
Immunogen, Inc.3$43
Teva Pharmaceuticals USA, Inc.3$42
Myovant Sciences Inc.2$38
Partner Therapeutics, Inc.2$36
Beone Medicines USA, Inc.2$35
Legend Biotech USA Inc.2$34
Spectrum Pharmaceuticals Inc.2$34
Clovis Oncology, Inc.3$34
Sun Pharmaceutical Industries Inc.2$28
EUSA Pharma (US) LLC2$26
Tempus AI, Inc1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,494 in reported general payments places this provider in the 80th percentile of 43 hematology providers in New Jersey.

See all hematology providers in New Jersey

Medicare billing

Part B allowed, 2024
$4,833,774
Medicare patients
462
Services billed
135,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcritEpoetin Alfa13$31,145
EliquisApixaban24$27,613
XareltoRivaroxaban22$17,777
Anastrozole43$1,128
Hydroxyurea16$149
Tramadol Hcl11$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonProcrit, Xarelto$930$48,92235 claims
PfizerEliquis$233$27,61324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 43 hematology providers in New Jersey.

Other hematology in Mountain Lakes

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →